World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
53669
World Ranking
13379
National Ranking
423

David Planchard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David Planchard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 623 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David Planchard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David Planchard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David Planchard is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on the fields of Medicine, with significant contributions to Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their work covers major topics including Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, and HER2/EGFR in Cancer Research.

Planchard has contributed to several recent scientific papers, such as:

  • "Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC" (2023, New England Journal of Medicine)
  • "Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer" (2021, New England Journal of Medicine)
  • "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023, Annals of Oncology)
  • "Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer" (2022, Nature Medicine)
  • "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023, Annals of Oncology)

Frequent co-authors include Benjamin Besse, Mihaela Aldea, Fabrice Barlési, Laura Mezquita, and Jordi Remón.

Planchard publishes regularly in venues such as:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Lung Cancer

Best Publications

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Scott J Antonia;Augusto Villegas;Davey Daniel;David Vicente

  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    Scott J. Antonia;Augusto Villegas;Davey Daniel;David Vicente

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

    Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

    Laura Mezquita;Edouard Auclin;Roberto Ferrara;Melinda Charrier

  • Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

    Kathryn C. Arbour;Laura Mezquita;Niamh Long;Hira Rizvi

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

    Roberto Ferrara;Laura Mezquita;Matthieu Texier;Jihene Lahmar

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

    James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  • Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

    Arnaud Scherpereel;Julien Mazieres;Laurent Greillier;Sylvie Lantuejoul

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

  • A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

    F Farace;F Farace;C Massard;N Vimond;F Drusch

  • Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

    A Lecharpentier;P Vielh;P Perez-Moreno;D Planchard

  • Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

    Myriam Delaunay;Jacques Cadranel;Amélie Lusque;Nicolas Meyer

  • Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

    Jhanelle E. Gray;Augusto Villegas;Davey Daniel;David Vicente

Frequent Co-Authors

Benjamin Besse
Benjamin Besse University of Paris-Saclay
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Julien Mazieres
Julien Mazieres Paul Sabatier University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Nathalie Chaput
Nathalie Chaput Institut Gustave Roussy
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Pasi A. Jänne
Pasi A. Jänne Harvard University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Scott J. Antonia
Scott J. Antonia Duke University
Silvia Novello
Silvia Novello University of Turin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in health careers but not ready to commit to the full journey of medical school, numerous online degree options offer rewarding pathways in healthcare. Many reputable universities now offer a him degree online, which prepares students for critical roles in maintaining and managing patient data—an increasingly important field as healthcare systems move to digital platforms.

Another popular career track is medical coding and billing. By earning a medical billing and coding certification online, you can quickly enter the workforce and play a key role in healthcare administration. For nurses looking to advance their expertise, affordable cheap online fnp programs enable registered nurses to expand their practice and become family nurse practitioners.

Likewise, existing RNs can benefit from the cheapest rn to bsn online programs, opening up leadership roles and advancing their careers without leaving their jobs. With flexible schedules and lower costs, these programs offer practical, accessible routes into vital healthcare professions.

Best Scientists Citing David Planchard

Trending Scientists

Recently Published Articles